1 / 12

NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C

NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C. Matt Johnson and Dr. Hunt / Asante / Jenkins. Hepatitis C - Transmission. There are 6 major types 40% are type 1, the rest are mainly type 2 + 3

hamish-cummings
Télécharger la présentation

NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins

  2. Hepatitis C - Transmission • There are 6 major types • 40% are type 1, the rest are mainly type 2 + 3 • Parenteral transmission ( IV drugs, blood transfusion, tattooing, electrolysis, ear piercing, acupuncture) • 6% Vertical transmission • HIV increases transmission

  3. Hepatitis C - Risks • 20% develop acute hepatitis • Jaundice and RUQ pain • Flu like illness with muscle aches • Decreased appetite and nausea • generalized weakness • 85% of those exposed will develop chronic hepatitis C (15% clear virus) • can take between 20 - 50y to develop • 20% develop cirrhosis in <20y • 33%do not progress ( or do after 50y )

  4. Hepatitis - Prevalence • Prevalence in England and Wales • 200 - 400,000 • 0.04% blood donors • 0.4% antenatal attenders (in London) • 1% GU clinic attenders • 50% IV drug

  5. Treatments • Interferon • 47% respond to monotherapy within 3-4/12 but some had to continue for 12/12 • PEGulated IFN • Ribavirin • Licenced for use in combination therapy • Combination Therapy (>1744 )

  6. Treatments • Interferon • Mode of action ? • Dose = 3 million units s/c 3 times a week • Ribavirin • Nucleoside analogue with a broad spectrum of antiviral activity (esp RNA V) • 500mg (for<75kg) or 600mg (for>75kg) PO bd • Combination therapy • SE’s as for IFN include - Flu, Thyroid, Haematology, Psychiatric, GI, Dermatology

  7. Trial Evidence • 19 published RCTs involving 3765 patients and 2 meta analysis • First presentation with Hepatitis C • Sustained virology responses were seen in • Monotherapy = 6 % (24/52) and 16% (48/52) • Combination = 33% and 41% • For those who responded to IFN alone but relapsed within < 6/12 • Monotherapy = 5% (24/52) • Combination = 49% (24/52)

  8. Treatments • Combination Therapy (>1744 ) • Type 1 = 17% sustained response after 24/52 • = 28% (approx 1/3) after 48/52 • Others = 67% (approx 2/3) after 24/52 • = no further benefit with another 24/52

  9. Follow Up • PCR, LBx, Genotype testing, Viral load • Type 1 are treated for 12/12 • Types 2 - 6 treated for 6/12 • 6/12 Combination therapy costs £4800 • Tests cost a further £200 • Weekly for 1/12 • Then 1/12 OPA • FBC and TFT

  10. Additional Information • 10-20% of combination therapy in the trials was discontinued due to SE’s (usually haematological) • Eradication is more likely if the patient is <40y, female, viral load <3.5milli/ml, minimal portal fibrosis • Unknown • Benefits of Combo in non-responders to monotherapy • Treatment in <18y, or in mild hepatitis

  11. Costs • 18 million per year • However increasing numbers are being diagnosed • Advances • Pegylated Interferon = longer acting version of IFN alpha ( more effective ) • Prognostic and cost implications in monitoring at the 1 and 3 month stage. This enables stopping or reduced lengths of therapy in non-responders and early responders respectively.

  12. Summary • Indications • histologically proven, previously untreated Hep C, without liver decompensation • adult patients who have previously responded to monotherapy but relapsed within <6/12 • cirrhosis with increased risks of HCC • Contraindications • Continuing IV drug use (excluding methadone) • alcoholics • decompensated liver disease

More Related